[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ting YANG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,59,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100607401","metabolic-and-immunomic-differential-analysis-of-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-100607401",false,"NCT07188077","Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma","Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Based on Metabolomics and Immunomics","Inclusion Criteria:\n\n1. Aged between 18 and 75 years.\n2. The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.\n3. Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.\n4. Case group patients must have complete supporting imaging and pathology data.\n\nExclusion Criteria:\n\n1. Presence of other systemic malignancies.\n2. Presence of severe infections or metabolic disorders.\n3. Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.\n4. Pregnant or lactating women.\n5. Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure).\n6. Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},20,"ESTIMATED","1 Year","OBSERVATIONAL","This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.",[27,28],"Primary Central Nervous System Lymphoma (PCNSL)","Diffuse Large B-Cell Lymphoma","RECRUITING","2025-11-15",{"date":32,"type":33},"2025-11-18","ACTUAL",{"date":35,"type":33},"2025-03-01",{"date":37,"type":22},"2027-03-01",{"name":39,"class":40},"Ting YANG","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":58,"locationsCount":41},"100608182","drug-eluting-bead-based-transarterial-chemoembolization-deb-tace-as-a-local-salvage-therapy-for-large-lesions-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-100608182","NCT07198230","Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* (1) Age 18 to 75 years; (2) Pathologically confirmed diffuse large B-cell lymphoma (DLBCL); (3) Recurrence or treatment resistance following multiple therapeutic regimens (e.g., chemotherapy, immunotherapy, targeted therapy), with at least one clearly defined bulky lesion (maximum diameter ≥5 cm or imaging evidence of bulky lesion); (4) Imaging studies (CT, MRI, or PET-CT) confirm rich blood supply to the lesion, making it suitable for transarterial interventional therapy; (5) History of favorable response to doxorubicin-based agents during prior systemic therapy; (6) ECOG performance status ≤ 2; (7) Blood counts, hepatic and renal function, and coagulation parameters meet the following criteria:\n\n  * Platelet count ≥ 30 × 10\\^9\u002FL;\n  * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the ULN;\n  * Serum creatinine ≤ 2.5 times the upper limit of normal (ULN);\n  * Prothrombin time international normalized ratio (INR) ≤ 1.5. (8) The patient has previously undergone at least one DEB-TACE treatment at this institution.\n\nExclusion Criteria:\n\n* (1) Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or other serious comorbidities rendering them unable to tolerate interventional therapy; (2) Patients with active or uncontrolled severe infections; (3) Patients with severe coagulation disorders or bleeding tendencies; (4) Pregnant or lactating women, or patients planning pregnancy during the study period; (5) Allergy or contraindications to drug-eluting microsphere materials or chemotherapy drugs; (6) Psychiatric disorders or cognitive impairment preventing treatment compliance and follow-up; (7) Other conditions deemed unsuitable for study participation by the investigator.",{"count":49,"type":22},10,"Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) for treating recurrent and refractory DLBCL masses. It seeks to establish a novel local salvage treatment strategy for such patients while providing preliminary theoretical foundations and clinical data to support future large-scale, multicenter clinical trials.",[28,52,53],"Relapsed and Refractory","Transarterial Chemoembolization",{"date":32,"type":33},{"date":35,"type":33},{"date":57,"type":22},"2027-09-01",{"name":39,"class":40},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":67,"targetDuration":69,"studyType":24,"phases":4,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100609106","hcmv-mirna-monitoring-after-allogeneic-hematopoietic-stem-cell-transplantation-using-pstm-qpcr-100609106","NCT07210242","HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR","Clinical Study on Monitoring Cytomegalovirus (HCMV) Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Using High-Performance miRNA Quantification Technology (PSTM-qPCR)","HSCT-HCMV01","Inclusion Criteria:\n\n\\- Patients scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n\nStem cell source includes peripheral blood stem cells and\u002For bone marrow plus peripheral blood.\n\nAbility to understand study procedures and provide written informed consent.\n\nVoluntary participation in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n\nChildren or individuals with severe cognitive impairment who cannot comply with blood sample collection.\n\nPatients with severe comorbidities or other medical conditions judged by the investigator to significantly interfere with study participation or follow-up.\n\nWithdrawal of informed consent during the study.\n\nClinical background or history that may introduce significant confounding effects, or when additional sampling frequency is deemed to pose undue risk to the participant.",{"count":68,"type":22},300,"12 Months","Human cytomegalovirus (HCMV) infection is one of the most common and serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Standard monitoring uses HCMV DNA testing, but this method may not detect the virus early enough to guide timely treatment.\n\nThis multicenter observational study will evaluate a new high-performance microRNA (miRNA) detection technology (PSTM-qPCR) for monitoring HCMV infection in allo-HSCT patients. Approximately 300 patients and their donors will be enrolled across several major transplant centers in China. Blood samples will be collected before and after transplantation to test for both HCMV-miRNA and HCMV-DNA. The study will compare the sensitivity and timing of miRNA detection with conventional DNA testing and explore whether miRNA can serve as an early biomarker of infection and related complications.\n\nThe goal is to improve early diagnosis and management of HCMV infection, reduce infection-related complications, and ultimately improve survival outcomes in patients undergoing allo-HSCT.",[72,73,74,75],"Cytomegalovirus Infections","Hematopoietic Stem Cell Transplantation","Virus Reactivation","Graft vs Host Disease",[77,78,79,80,81,82,83,84,85,86],"Allogeneic Hematopoietic Stem Cell Transplantation","Human Cytomegalovirus","MicroRNA","HCMV-miRNA","PSTM-qPCR","Viral Reactivation","Infection Monitoring","Early Diagnosis","Biomarker","GVHD","NOT_YET_RECRUITING","2025-09-29",{"date":90,"type":33},"2025-10-07",{"date":92,"type":22},"2025-10-10",{"date":94,"type":22},"2028-10-10",{"name":39,"class":40},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":19,"enrollmentInfo":105,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100475091","lung-health-of-early-copd-a-multi-center-cohort-study-100475091","NCT05466396","Lung Health of Early COPD: A Multi-center Cohort Study","Lung Health of Early Chronic Obstructive Pulmonary Disease: A Multi-center Cohort Study","LHEC","Inclusion Criteria:\n\n1. Gender: male or female\n2. Age: 35-75 years old\n3. post-bronchodilator spirometry: FEV1\u002FFVC \\\u003C 0.8 and FEV1%pred ≥80%\n\nExclusion Criteria:\n\n1. Other diseases may affect lung function, like lung cancer, bronchiectasis, interstitial lung disease or chest surgery.\n2. BMI \\> 35 kg\u002Fm2\n3. Dementia or other severe neurological disease\n4. Pregnancy\n5. Conditions that contraindicated lung function test","35 Years",{"count":106,"type":22},1550,"This is a multi-center, prospective, cohort study in early COPD patients. This study aims to elucidate the lung function decline and its association with smoking and other risk factors. Other biomarkers and image markers from chest CT scan are also analyzed to investigate the lung function in early COPD patients.",[109],"COPD",[111,112,113],"early COPD","spirometry","lung health","2025-02-13",{"date":116,"type":33},"2025-02-17",{"date":118,"type":33},"2022-08-01",{"date":120,"type":22},"2027-12-31",{"name":39,"class":40},2,""]